

If you're hospitalized with COVID-19

# **VEKLURY<sup>®</sup> COULD HELP YOUR PATH TO RECOVERY**

Talk to a healthcare provider to see if VEKLURY may be an option for you.

## **WHAT IS VEKLURY?**

**VEKLURY** is a prescription medicine used to treat COVID-19 in adults and children weighing at least 3 pounds who are:

- Hospitalized, or
- Not hospitalized, have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Talk to a healthcare provider to see if VEKLURY may be an option for you.

## **IMPORTANT SAFETY INFORMATION**

**Who should not take VEKLURY?**

**Do not take VEKLURY if you:**

- Are allergic to remdesivir or any of the other ingredients in VEKLURY.

Please click for [Patient Prescribing Information](#) about VEKLURY at the end of this document.

# PATIENTS RECOVERED FASTER WITH VEKLURY® (remdesivir)



In a study, the effectiveness of VEKLURY was **compared to placebo\*** in 1062 adult men and women of different races and ethnic backgrounds who were hospitalized with mild-to-moderate or severe COVID-19.

The median† number of days to **recovery for patients treated with VEKLURY was 10 days vs 15 days** for patients who received placebo. Recovery referred to patients who were no longer hospitalized or hospitalized but did not require ongoing medical care for COVID-19.



**Patients on VEKLURY spent less days on oxygen:** 913 patients were on oxygen at the start of the study, and those taking VEKLURY spent a median‡ of **8 days less on oxygen** compared to placebo.

## VEKLURY has a generally well-tolerated safety profile.



May be used in children and adult patients, and patients with kidney or liver problems.

**Side effects with VEKLURY** were similar to those in the group taking placebo.

The most common side effect in people taking VEKLURY was nausea.

\*A placebo is a treatment that does not contain medication. It is used as a comparison when testing treatments.

†The medians demonstrate that half of patients treated with VEKLURY recovered within 10 days while half of patients receiving placebo recovered within 15 days.

‡The median demonstrates that half of patients treated with VEKLURY spent 8 days less on oxygen.



IN THE UNITED STATES  
**MORE THAN 3.1 MILLION  
PATIENTS WITH COVID-19 HAVE  
BEEN TREATED WITH VEKLURY®**

As of July 2020–January 2024

Talk to a healthcare provider to see if VEKLURY may be an option for you.

### IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of VEKLURY?

Serious side effects of VEKLURY may include:

- **Allergic reactions.** VEKLURY can cause allergic reactions during or after infusion. Tell your healthcare provider right away if you get any of the following symptoms: changes to heart rate, rash, fever, nausea, sweating, shortness of breath, or wheezing, or swelling of the lips, face, or throat.
- **Increase in liver enzymes.** Increases in the amount of liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment and may stop your treatment with VEKLURY if you develop new or worsening liver problems.

**The most common side effect** in people receiving VEKLURY is nausea. Tell your healthcare provider if you have any side effects that bother you or do not go away.

Please click for [Patient Prescribing Information](#) about VEKLURY at the end of this document.

# QUESTIONS ABOUT VEKLURY?

Here are some answers to common questions you may have.

## WHAT IS VEKLURY?

VEKLURY is an FDA-approved antiviral medication that helps treat patients with COVID-19. The coronavirus that causes COVID-19 spreads in the body by making copies of itself. VEKLURY interrupts the way the virus copies itself.

## WHO IS IT FOR?

VEKLURY is prescribed for adults, as well as children who weigh at least 3 pounds who are:

- Hospitalized
- Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19

Talk to your healthcare provider to see if VEKLURY may be an option for you.

## ARE THERE ANY SIDE EFFECTS?

The most common side effect in people receiving VEKLURY is nausea. Tell your healthcare provider if you have any side effects that bother you or do not go away.

## IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare provider before receiving VEKLURY?

- **All your health problems.** Be sure to tell your healthcare provider if you have or have had any allergies, liver problems, or any serious illnesses.
- **If you are pregnant or breastfeeding:** It is not known if VEKLURY may harm your unborn baby if taken during the first trimester. VEKLURY can pass into your breast milk. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.
- **All the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may affect how VEKLURY works. **Especially tell your healthcare provider if you are taking any medicines that contain chloroquine phosphate or hydroxychloroquine sulfate.**

## HOW IS IT GIVEN?

VEKLURY is given by an intravenous (IV) infusion. IV infusion delivers the medication directly into your bloodstream through a vein. Your healthcare provider will decide how many doses of VEKLURY you will need.

## WHAT IS THE DIFFERENCE BETWEEN AN ANTIVIRAL AND A VACCINE?

Antiviral medications, like VEKLURY, help your body fight viruses that cause disease. A vaccine is a type of medicine taken *before* infection to help prevent illness.

## IMPORTANT SAFETY INFORMATION (cont'd)

How is VEKLURY given?

- Hospitalized: VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need.
- Not hospitalized: VEKLURY is given to you through a vein by IV infusion one time each day for 3 days.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.FDA.gov/medwatch](http://www.FDA.gov/medwatch), or call 1-800-FDA-1088.

Please click for [Patient Prescribing Information](#) about VEKLURY at the end of this document.





# #1 PRESCRIBED ANTIVIRAL FOR PATIENTS HOSPITALIZED WITH COVID-19

Premier, Inc., and HealthVerity, Inc.; February 2023 to February 2024.

**HAVE MORE QUESTIONS  
ABOUT VEKLURY®?**

Talk to your healthcare provider to see  
if **VEKLURY** may be an option for you.

Visit **VEKLURY.com** to learn more.

Please click for **Important Safety Information**  
throughout and **Patient Prescribing Information**  
about **VEKLURY** at the end of this document.



VEKLURY, the VEKLURY Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners.  
© 2024 Gilead Sciences, Inc. All rights reserved. US-VKYC-0030 05/24



**PATIENT INFORMATION**

VEKLURY® (VEK-lur-ee)  
(remdesivir)  
for injection

VEKLURY® (VEK-lur-ee)  
(remdesivir)  
injection

**What is VEKLURY?**

VEKLURY is a prescription medicine used for the treatment of coronavirus disease 2019 (COVID-19) in adults and children weighing at least 3 pounds (1.5 kg) who are:

- Hospitalized, **or**
- Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

It is not known if VEKLURY is safe and effective in children weighing less than 3 pounds (1.5 kg).

**Do not take VEKLURY if you are allergic to remdesivir or any of the ingredients in VEKLURY.** See the end of this leaflet for a complete list of ingredients in VEKLURY.

**Before receiving VEKLURY, tell your healthcare provider about all of your medical conditions, including if you:**

- have liver problems
- are pregnant or plan to become pregnant. It is not known if VEKLURY may harm your unborn baby if taken during the first trimester of pregnancy. **Tell your healthcare provider right away if you are or if you become pregnant.**  
**Pregnancy Registry:** There is a pregnancy registry for individuals who receive VEKLURY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.
- are breastfeeding or plan to breastfeed. VEKLURY can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEKLURY may interact with other medicines.

**Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate.**

**How will I receive VEKLURY?**

- **Hospitalized:** VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need.
- **Not hospitalized:** VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for 3 days.
- Your healthcare provider will do certain blood tests before starting and during treatment with VEKLURY.

**What are the possible side effects of VEKLURY?**

**VEKLURY may cause serious side effects, including:**

- **Allergic reactions.** Allergic reactions can happen during or after infusion with VEKLURY. Your healthcare provider will monitor you for signs and symptoms of allergic reactions during your infusion and for at least 1 hour after your infusion. Tell your healthcare provider right away if you get any of the following signs and symptoms of an allergic reaction:
  - changes in your heart rate
  - fever
  - shortness of breath, wheezing
  - swelling of the lips, face, or throat
  - rash
  - nausea
  - sweating
  - shivering
- **Increase in liver enzymes.** Increases in liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment with VEKLURY as needed. Your healthcare provider may stop treatment with VEKLURY if you develop liver problems.

**The most common side effect of VEKLURY** is nausea.

These are not all of the possible side effects of VEKLURY.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**General information about the safe and effective use of VEKLURY.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about VEKLURY that is written for healthcare professionals.

**What are the ingredients in VEKLURY?**

**Active ingredient:** remdesivir

**Inactive ingredients:**

**VEKLURY for injection:** betadex sulfobutyl ether sodium and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.

**VEKLURY injection:** betadex sulfobutyl ether sodium, Water for Injection, USP, and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.

Manufactured and distributed by: Gilead Sciences, Inc., Foster City, CA 94404

VEKLURY is a trademark of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.

© 2024 Gilead Sciences, Inc. All rights reserved.

214787-GS-017

For more information, call 1-800-445-3235 or go to [www.VEKLURY.com](http://www.VEKLURY.com).

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 02/2024